Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARWR | US
-0.40
-2.08%
Healthcare
Biotechnology
30/06/2024
04/10/2024
18.82
19.01
19.27
18.68
Arrowhead Pharmaceuticals Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2 which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4 which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989 a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals Inc. to develop JNJ-75220795 ARO-JNJ2 and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A. Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals Inc. was incorporated in 1989 and is headquartered in Pasadena California.
View LessNegative Momentum (Declining Price)
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
27.2%1 month
46.7%3 months
48.7%6 months
52.4%-
111.11
7.40
1.37
0.51
-11.02
108.35
-1.32
-529.78M
2.34B
2.34B
-
-2.79K
9.80
-94.30
-151.84
9.75
8.54
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.09
Range1M
6.05
Range3M
12.26
Rel. volume
0.57
Price X volume
12.60M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
SPRINGWORKS THERAPEUTICS INC. | SWTX | Biotechnology | 32.64 | 2.42B | -0.58% | n/a | 1.27% |
IBRX | IBRX | Biotechnology | 3.43 | 2.39B | -3.92% | n/a | -143.04% |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 40.84 | 2.35B | -2.18% | n/a | 16.11% |
Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 45.02 | 2.35B | 3.61% | n/a | 3.62% |
KEROS THERAPEUTICS INC. | KROS | Biotechnology | 60.9 | 2.30B | -0.67% | n/a | 3.32% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.02 | 0.76 | Cheaper |
Ent. to Revenue | 108.35 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 7.40 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 48.67 | 74.67 | Lower Risk |
Debt to Equity | 1.37 | -1.82 | Expensive |
Debt to Assets | 0.51 | 0.26 | Expensive |
Market Cap | 2.34B | 3.73B | Emerging |